Cancer Commons founder Marty Tenenbaum, Ph.D., will speak at the upcoming Bio-IT World Conference & Expo in Boston, which runs May 15 to 18. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the potential for artificial intelligence to help find better cancer treatments.
AI can beat go and drive cars, but can it beat cancer? Every year, many thousands of cancer patients die unnecessarily because their doctors do not know the optimal way to treat them with currently available therapies. Physicians and patients alike struggle with information overload and conflicting expert opinions in making treatment decisions. Moreover, effective treatments increasingly involve intelligently designed, individually tailored, sequences and combinations, and there are far more plausible multi-drug regimens than can be efficiently tested in clinical trials. AI can help by connecting physicians and patients to the right information at the right time, and by planning and coordinating the thousands of formal and informal treatment experiments that take place daily in oncology, to optimize individual outcomes and maximize collective knowledge. We will describe a developing global collaboration to realize this bold vision, involving leading oncologists, cancer and data scientists, and AI experts from both academia and industry, and discuss opportunities for all to participate.
The Bridging Clinical Research & Clinical Health Care Collaborative is “the only forum where clinical research and health care professionals come together to envision a collaborative solution that strengthens the connection between clinical research and health care.” Learn more about the event at https://www.bridgingclinical.com/agenda/.
Cancer Commons founder Marty Tenenbaum, Ph.D., will speak at the upcoming Precision Medicine World Conference (PMWC) in Durham, NC, which runs May 24–25. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the organization’s ongoing efforts to address challenges to knowledge-sharing in precision oncology.
Read the synopsis of Marty’s presentation, entitled “Is An Additional Path to FDA Approval Possible?”:
This talk will explore the question: When faced with certain death, it is acceptable to accept less than 100% proven safety and efficacy?Patients with glioblastoma and certain other cancers with dire prognoses do not have the time to wait for new treatments to be fully approved by the FDA. Is it time to add “conditional approval” as an additional pathway to approval for these patients? In this session, a plan will be proposed by which the FDA could conditionally approve a treatment that has been proven safe in a clinical trial(s) with at least 25 patients, and has demonstrated biologic activity. Therefore, this treatment could not be denied by insurance as being “experimental”. However, the requires patients using these drugs to participate in a registry through which their physicians submit details on the treatments, side effects and outcomes. The FDA’s periodic review of the registry data would lead to a range of outcomes from full approval to the conditional approval being revoked.
Marty’s talk takes place on May 24 at 2:45 pm. For more information, visit the PMWC website.
Oncologist and Cancer Commons Medical Director Kevin Knopf, MD, will speak next month at TiEcon 2017, a technology conference in Santa Clara, CA. He’ll join three other experts to discuss the future of personalized medicine. From the program:
A new era of personalized medicine has made its way into the world of healthcare. We will discuss novel approaches for designing disease treatment and prevention that integrates with an individual’s genetic profile, environment and lifestyle.The future is here — let’s hear from industry luminaries on how digital health entrepreneurs and the healthcare industry as a whole are preparing for massive disruption.
Kevin’s presentation will take place on May 5 at 3:00 pm. For more information, visit the TiEcon website.
This year, the Annual Meeting of the American Society of Clinical Oncology (ASCO) did not produce any truly groundbreaking revelations about new treatments for lung cancer. However, researchers did report quite a few positive findings, and some disappointing ones. I have summarized some of the more prominent presentations below. Continue reading…
Cancer Commons founder Marty Tenenbaum spoke last weekend at Medicine X, Stanford University’s conference for new ideas in medicine and healthcare. He told the story of his personal melanoma fight, and how difficult it was to find the information he needed to beat his cancer. This experience led him to found Cancer Commons, with the goal of developing a rapid learning platform to help patients explore their options and make the best, most personalized decisions about their cancer care.
Every year, scientists, doctors, and representatives from pharmaceutical, diagnostics, and technology companies gather in Silicon Valley to talk shop at the Personalized Medicine World Conference (PMWC). For 2 days, they discuss the triumphs and challenges of diagnosing and treating diseases based on patients’ distinct genetic characteristics.
This year, the PMWC status quo was interrupted by a not-so-unlikely guest: the patient. Cancer Commons joined the event’s organizers to cohost a series of informative presentations for patients and advocates, delivered by doctors and researchers, as well as patients and advocates themselves. Continue reading…
Personalized oncology is changing the cancer treatment landscape. Increasingly, patients are treated according to the distinct genetics of their tumors. To realize the full benefits of this shift, cancer patients and advocates must be engaged and informed. Cancer Commons has joined the Personalized Medicine World Conference (PMWC) to co-host a special two-day track for cancer patients and advocates. Attendees will have the opportunity to discuss personalized medicine with each other and with researchers, clinicians, and industry leaders. Distinguished speakers will present the latest advances in personalized oncology and discuss its promise for the future.
PMWC is the largest and most established global conference on personalized medicine. It provides a platform for clinical, scientific, industry, and mobile health stakeholders to collaborate and catalyze further change. Cancer patients and advocates can register for the Patient & Advocate Program (Track 4) at a discounted fee.
PMWC 2014 will take place January 27-28, 2014, at the Computer History Museum in Mountain View, CA.
“Exciting collaborations are integrating multiple research programs with critical investments and leadership by the Melanoma Research Alliance (MRA), a unique foundation launched by Debra and Leon Black under the auspices of the Milken Institute. MRA’s mission is to accelerate scientific discovery to eliminate death and suffering due to melanoma. Discussions of cutting-edge melanoma research results and clinical care strategies took place on February 27-28, 2013, in Washington, DC, at the MRA’s Fifth Annual Scientific Retreat.”